Hypermethylation of the MGMT (O6-methylguanine-DNA methyltransferase) promoter is considered an important predictor of a good response to chemotherapy with temozolomide (TMZ) in glioma patients [23,24]. Here, MGMT is linked to central nervous system cancer.